The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study (AtheroRemoIVUS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Patrick W. Serruys, Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT01789411
First received: February 6, 2013
Last updated: February 11, 2013
Last verified: February 2013

February 6, 2013
February 11, 2013
November 2008
December 2013   (final data collection date for primary outcome measure)
Vulnerable plaque as determined by intravascular ultrasound [ Time Frame: cross-sectional (time of baseline coronary angiography, no follow-up) ] [ Designated as safety issue: No ]
The primary objective is to correlate coronary plaque phenotype as determined by intravascular ultrasound with genetic profile and circulating biomarkers. Primary endpoint is the presence of vulnerable plaque as determined by intravascular ultrasound.
Same as current
Complete list of historical versions of study NCT01789411 on ClinicalTrials.gov Archive Site
Major adverse cardiac events [ Time Frame: 1-year follow-up ] [ Designated as safety issue: No ]
The secondary objective is to assess the prognostic value of novel biomarkers and plaque phenotypes as determined by intravascular ultrasound and near-infrared spectroscopy. Secondary endpoint is 1-year incidence of major adverse cardiac events.
Same as current
Not Provided
Not Provided
 
The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study
The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study

The AtheroRemo-IVUS study aims to investigate the relation of coronary plaque phenotype and vulnerability as determined by intravascular ultrasound and near infrared spectroscopy with genetic profile and novel circulating biomarkers. AtheroRemo-IVUS is a prospective, observational, cohort study of patients who underwent coronary catheterization for acute coronary syndrome or stable angina pectoris. Prior to the catheterization procedure, blood samples were drawn for biomarker measurements and genetic analyses. Subsequent to the catheterization procedure, intravascular ultrasound is performed in a non-culprit coronary artery. In patients who are also participating in the AtheroRemo-NIRS substudy, near-infrared spectroscopy is additionally performed in the same non-culprit vessel. Primary endpoint is the presence of vulnerable plaque as determined by intravascular ultrasound. Secondary endpoint is long-term incidence of major adverse cardiac events. Results from AtheroRemo-IVUS are expected to improve our knowledge on the role of genetic profile and inflammation in the development of atherosclerosis and vulnerable plaques. Furthermore, novel biomarkers and intracoronary imaging techniques will be validated in this study.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Arterial blood samples

Probability Sample

Patients with acute coronary syndrome or stable angina pectoris, referred for percutaneous coronary intervention or coronary angiography

Coronary Artery Disease
  • Other: Drawing blood samples
    Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
  • Device: Coronary intravascular ultrasound imaging
    Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
  • Device: Coronary near-infrared spectroscopy
    Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
ATHEROREMO-IVUS cohort
Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
Interventions:
  • Other: Drawing blood samples
  • Device: Coronary intravascular ultrasound imaging
  • Device: Coronary near-infrared spectroscopy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
800
Not Provided
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients of both sexes, more than 21 years old.
  2. Patients with stable angina pectoris (CCS Class 1, 2, 3 or 4) or unstable angina pectoris (Braunwald Class 1-3, B-C) or patients with documented silent ischemia or patients with an acute myocardial infarction (STEMI and NSTEMI).
  3. Patients eligible for coronary revascularization in the native coronary artery/arteries.
  4. Willing and able to comply with the specified follow-up evaluation.
  5. Written informed consent obtained.
  6. Flow-limiting stenosis (diameter stenosis ≥50% by QCA or visual estimate) that is held responsible for angina pectoris or acute coronary syndrome
  7. The study vessel has not undergone percutaneous coronary intervention in the last 8 months.

Exclusion Criteria:

  1. Braunwald class IA, IIA, IIIA (angina caused by non-cardiac illness).
  2. Women who are pregnant or women of childbearing potential who do not use adequate contraception.
  3. Known allergies to aspirin, clopidogrel bisulfate (Plavix ®), Ticlopdine (Ticlid ®) heparin, stainless steel, copper or a sensitivity to contrast media which cannot be adequately pre-medicated.
  4. Previous participation in this study or participation in another study with any investigational drug or device within the past 30 days (study participation ends after completion of the final follow-up.)
  5. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult.
  6. Planned or being status post coronary bypass surgery.
  7. Planned major non-cardiac surgery.
  8. Impaired renal function (creatinine >2 mg/dl or >150 umol/L).
  9. The subject has a history of bleeding diathesis or coagulopathy.
  10. The subject suffered disabling stroke within the past year.
  11. 3-vessel coronary artery and/or Left main disease with > 50% stenosis.
  12. Minimal lumen diameter <2mm in the segments to be analyzed within the study vessel.
  13. Diameter Stenosis >70% or total occlusion of the study vessel.
  14. In case the study-vessel has been stented previously (>8 months ago), more than 1/3 proximal of the study vessel (at least 40mm in length) should be available for examination (i.e., outside the length of the stent plus 5mm proximal to the stent).
  15. Poor LV function as assessed by Echo or by Angiography.
  16. The proximal vessel is moderately to severely tortuous (moderate: 2 bends >75 degrees or one bend >90 degrees) in the segment(s) to be analyzed.
  17. Known tendency to coronary vasospasm.
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01789411
EMC MEC 2008-210
No
Patrick W. Serruys, Erasmus Medical Center
Erasmus Medical Center
Not Provided
Study Chair: Patrick W Serruys, MD, PhD Erasmus MC
Erasmus Medical Center
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP